KeyBank National Association
RVNC

KeyBank National Association’s Revance Therapeutics, Inc. RVNC Stock Holding History

KeyBank National Association’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,021
Closed -$330K – 1077
2023
Q2 		$330K Buy
13,021
+391
+3% +$12.2K ﹤0.01% 852
2023
Q1 		$407K Sell
12,630
-2,400
-16% -$74.8K ﹤0.01% 775
2022
Q4 		$277K Buy
15,030
+5,740
+62% +$131K ﹤0.01% 893
2022
Q3 		$251K Sell
9,290
-3,632
-28% -$73.7K ﹤0.01% 911
2022
Q2 		$179K Buy
+12,922
New +$199K ﹤0.01% 1017

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KeyBank National Association's RVNC Position: Q3 2023 in Review

KeyBank National Association sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 13,021 shares — an estimated $330K sold.

KeyBank National Association first reported a position in RVNC in Q2 2022 and held it in 5 quarters. The position peaked at $407K in Q1 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • KeyBank National Association reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • KeyBank National Association sold 13,021 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $330K.
  • KeyBank National Association first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 5 quarters.
  • KeyBank National Association's Revance Therapeutics, Inc. position peaked at $407K in Q1 2023.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on KeyBank National Association's 13F filing for Q3 2023, filed 8 Nov 2023.